Ugo Cavallaro

Milan, 20139, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

Epiproteomic profiling identifies histone H4 hyperacetylation as a prognostic marker in pleural mesothelioma.

Epiproteomic profiling identifies histone H4 hyperacetylation as a prognostic marker in pleural mesothelioma.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: May 08, 2026

Quantitative Proteomics and Phosphoproteomics Analysis of Patient-Derived Ovarian Cancer Stem Cells.

Quantitative Proteomics and Phosphoproteomics Analysis of Patient-Derived Ovarian Cancer Stem Cells.

Journal: Molecular & cellular proteomics : MCP

Published: September 06, 2024

Early tolerance and late persistence as alternative drug responses in cancer.

Early tolerance and late persistence as alternative drug responses in cancer.

Journal: Nature communications

Published: April 11, 2024

Tumor microenvironment-induced FOXM1 regulates ovarian cancer stemness.

Tumor microenvironment-induced FOXM1 regulates ovarian cancer stemness.

Journal: Cell death & disease

Published: April 09, 2024

Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth.

Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth.

Journal: Molecular cancer therapeutics

Published: December 06, 2023

Matrix Gla Protein drives stemness and tumor initiation in ovarian cancer.

Matrix Gla Protein drives stemness and tumor initiation in ovarian cancer.

Journal: Cell death & disease

Published: January 18, 2023

Patient-Derived In Vitro Models of Ovarian Cancer: Powerful Tools to Explore the Biology of the Disease and Develop Personalized Treatments.

Patient-Derived In Vitro Models of Ovarian Cancer: Powerful Tools to Explore the Biology of the Disease and Develop Personalized Treatments.

Journal: Cancers

Published: December 02, 2022

Rational design, synthesis, and pharmacological evaluation of a cohort of novel beta-adrenergic receptors ligands enables an assessment of structure-activity relationships.

Rational design, synthesis, and pharmacological evaluation of a cohort of novel beta-adrenergic receptors ligands enables an assessment of structure-activity relationships.

Journal: European journal of medicinal chemistry

Published: October 05, 2022

Development of a Multiprotein Classifier for the Detection of Early Stage Ovarian Cancer.

Development of a Multiprotein Classifier for the Detection of Early Stage Ovarian Cancer.

Journal: Cancers

Published: May 19, 2022

Antagonistic L1 Adhesion Molecule Mimetic Compounds Inhibit Glioblastoma Cell Migration In Vitro.

Antagonistic L1 Adhesion Molecule Mimetic Compounds Inhibit Glioblastoma Cell Migration In Vitro.

Journal: Biomolecules

Published: November 27, 2021

Integrated molecular profiling of patient-derived ovarian cancer models identifies clinically relevant signatures and tumor vulnerabilities.

Integrated molecular profiling of patient-derived ovarian cancer models identifies clinically relevant signatures and tumor vulnerabilities.

Journal: International journal of cancer

Published: September 11, 2021

VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status.

VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status.

Journal: Journal of hematology & oncology

Published: August 04, 2021

Showing 1-12 of 36

Last Updated: 09/26/2026